These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 29260929)

  • 1. Switching basal insulins in type 2 diabetes: practical recommendations for health care providers.
    Anderson SL; Trujillo JM; Anderson JE; Tanenberg RJ
    Postgrad Med; 2018 Mar; 130(2):229-238. PubMed ID: 29260929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insulin degludec--the impact of a new basal insulin on care in type 2 diabetes.
    Khunti K; Cos X; Rutten G
    Prim Care Diabetes; 2014 Jul; 8(2):119-25. PubMed ID: 24207030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The importance of postprandial glycemic control: optimizing add-on therapy to basal insulin.
    Shaefer CF; Anderson J
    Postgrad Med; 2016 Jan; 128(1):137-44. PubMed ID: 26548422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin therapy for diabetes mellitus: treatment regimens and associated costs.
    Charbonnel B; Penfornis A; Varroud-Vial M; Kusnik-Joinville O; Detournay B
    Diabetes Metab; 2012 Apr; 38(2):156-63. PubMed ID: 22172400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insulin degludec, a long-acting once-daily basal analogue for type 1 and type 2 diabetes mellitus.
    Berard L; MacNeill G
    Can J Diabetes; 2015 Feb; 39(1):4-9. PubMed ID: 25065475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical use of the co-formulation of insulin degludec and insulin aspart.
    Kumar A; Awata T; Bain SC; Ceriello A; Fulcher GR; Unnikrishnan AG; Arechavaleta R; Gonzalez-Gálvez G; Hirose T; Home PD; Kaku K; Litwak L; Madsbad S; Pinget M; Mehta R; Mithal A; Tambascia M; Tibaldi J; Christiansen JS
    Int J Clin Pract; 2016 Aug; 70(8):657-67. PubMed ID: 27384031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Newer insulins in type 2 diabetes.
    Gale EA
    BMJ; 2012 Sep; 345():e4611. PubMed ID: 22968720
    [No Abstract]   [Full Text] [Related]  

  • 8. Novel and Emerging Insulin Preparations for Type 2 Diabetes.
    Cheung KK; Alexander P
    Can J Diabetes; 2015 Dec; 39 Suppl 5():S160-6. PubMed ID: 26653255
    [No Abstract]   [Full Text] [Related]  

  • 9. Willingness-to-pay for benefits associated with basal insulin treatment of type 2 diabetes.
    Jendle J; Ridderstråle M; Torfvitt O; Ericsson A; Larsen S
    J Med Econ; 2012; 15(2):261-3. PubMed ID: 22142237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin analogs versus human insulin in type 2 diabetes.
    Migdalis IN
    Diabetes Res Clin Pract; 2011 Aug; 93 Suppl 1():S102-4. PubMed ID: 21864739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fixed combination of insulin and a glucagon-like peptide-1 analog for the treatment of type 2 diabetes, exemplified by insulin degludec and liraglutide.
    Vedtofte L; Knop FK; Vilsbøll T
    Expert Rev Clin Pharmacol; 2015 May; 8(3):273-82. PubMed ID: 25816888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of insulin degludec compared with insulin glargine for patients with type 2 diabetes treated with basal insulin - from the UK health care cost perspective.
    Evans M; Wolden M; Gundgaard J; Chubb B; Christensen T
    Diabetes Obes Metab; 2014 Apr; 16(4):366-75. PubMed ID: 24373113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A patient centred approach to basal insulin choice for the management of type 2 diabetes mellitus.
    Kalra S; Gupta Y
    J Pak Med Assoc; 2016 Mar; 66(3):360-1. PubMed ID: 26968297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Long-acting insulins in the treatment of type 2 diabetes and their position in the current treatment algorithm].
    Haluzík M
    Vnitr Lek; 2017; 63(2):87-92. PubMed ID: 28334539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Switching to multiple daily injection therapy with glulisine improves glycaemic control, vascular damage and treatment satisfaction in basal insulin glargine-injected diabetic patients.
    Yanagisawa K; Ashihara J; Obara S; Wada N; Takeuchi M; Nishino Y; Maeda S; Ishibashi Y; Yamagishi S
    Diabetes Metab Res Rev; 2014 Nov; 30(8):693-700. PubMed ID: 24639403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The development of new basal insulins: is there any clinical advantage with their use in type 2 diabetes?
    Maiorino MI; Petrizzo M; Capuano A; Giugliano D; Esposito K
    Expert Opin Biol Ther; 2014 Jun; 14(6):799-808. PubMed ID: 24673155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin detemir (levemir), a new long-acting insulin.
    Med Lett Drugs Ther; 2006 Jul; 48(1238):54-5. PubMed ID: 16841022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of switching patients with type 2 diabetes from insulin glargine to insulin detemir in Chinese setting: a health economic model based on the PREDICTIVE study.
    Yang L; Christensen T; Sun F; Chang J
    Value Health; 2012; 15(1 Suppl):S56-9. PubMed ID: 22265068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can a fixed-ratio combination of insulin degludec and liraglutide help Type 2 diabetes patients to optimize glycemic control across the day?
    Simpson R; King A
    Expert Rev Clin Pharmacol; 2015 Mar; 8(2):179-88. PubMed ID: 25697410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of once-daily insulin detemir in patients with type 2 diabetes treated with oral hypoglycemic agents in routine clinical practice.
    Ross S; Dzida G; Ji Q; Kaiser M; Ligthelm R; Meneghini L; Nazeri A; Orozco-Beltran D; Pan C; Svendsen AL;
    J Diabetes; 2014 May; 6(3):243-50. PubMed ID: 24103141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.